Clinical Trial Update: Study of Tremelimumab in Patients With Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for tremelimumab in advanced solid tumors completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer
• Urothelial Bladder Cancer

Drugs mentioned

• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Urothelial Bladder Cancer, Triple-negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2019-03-05